Skip to main content
Log in

Reformulation of a new vancomycin analog: An example of the importance of buffer species and strength

  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

The purpose of this research was to use our previously validated dynamic injection apparatus as a rapid method for screening pH-adjusted formulations of a new vancomycin analog, Van-An, for their potential to precipitate upon dilution. In 1 vial, Van-An was reconstituted according to the manufacturer’s instructions. In a separate vial, the Van-An formulation’s existing phosphate buffer species was supplemented with acetate buffer, which has a pKa in the desired range: between the pH values of the formulation (pH 3.9) and blood (pH 7.4). The formulations were injected using the dynamic injection apparatus into a flowing stream of isotonic Sorensen’s phosphate buffer at rates of 0.25, 0.5, 1, and 2 mL/min. The peaks obtained with the spectrophotometer were reproducible for each injection rate/formulation combination. For the phosphate-buffered formulation, the least amount of precipitation was obtained at the 0.25 mL/min injection rate. Acetate buffer was able to substantially reduce such precipitation, even at the highest injection rate. The opacity peaks for the formulation with the acetate addition were significantly smaller (P<.05) than those obtained for the unaltered formulation at all 4 injection rates. The results suggest that acetate is a better buffer species than phosphate for the pH range defined. Furthermore, we present evidence to support a generally applicable approach to screening new formulations of drug products that may be clinically useful for reducing the incidence of phlebitis in humans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hadaway L, Chamallas SN. Vancomycin. J Infus Nurs. 2003;26: 278–284.

    Article  PubMed  Google Scholar 

  2. Takács-Novák K, Noszál B, Tokes-Kovesdi M, Szasz G. Acid base properties and proton-speciation of vancomycin. Int J Pharm. 1993;89:261–263.

    Article  Google Scholar 

  3. Malabarba A, Ciabatti R. Glycopeptide derivatives. Curr Med Chem. 2001;8:1759–1773.

    Article  CAS  PubMed  Google Scholar 

  4. Salaria M. Teicoplanin. Indian Pediatr. 2001;38:372–375.

    CAS  PubMed  Google Scholar 

  5. Douchin K, Shaw J, Spencer E, Seroogy J, Barriere S, Wilbraham D. Single dose pharmacokinetics (PK) of telavancin (TLV) in healthy elderly subjects. Clin Microbiol Infect. 2004;10:275.

    Google Scholar 

  6. Douchin K, Shaw J, Spencer E, Seroogy J, Barriere S, Wilbraham D. Single dose pharmacokinetics (PK) of telavancin (TLV) in subjects with renal dysfunction. Clin Microbiol Infect. 2004;10:276.

    Google Scholar 

  7. Internet press release from Biospase Beat. Biotechnology and Pharmaceutical News. Available at: http://www.biospace.com/news_ story.cfm?StoryID=14456320&full=1. Accessed: December 28, 2004.

  8. Targocid for Injection package insert. Available at: http://home. intekom.com/pharm/roussel/targocid.html. Accessed: December 28, 2004.

  9. Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs. 2004;64:913–936.

    Article  PubMed  Google Scholar 

  10. Taxis K, Barber N. Ethnographic study of incidence and severity of intravenous drug errors. BMJ. 2003;326:1–4.

    Article  Google Scholar 

  11. Lanbeck P, Odenholt I, Paulsen O. Antibiotics differ in their tendency to cause infusion phlebitis: a prospective observational study. Scand J Infect Dis. 2002;34:512–519.

    Article  CAS  PubMed  Google Scholar 

  12. Johnson JLH, He Y, Yalkowsky SH. Prediction of precipitation-induced phlebitis: a statistical validation of an in vitro model. J Pharm Sci. 2003;92:1574–1581.

    Article  CAS  PubMed  Google Scholar 

  13. Rowland M, Tozer TM. Clinical Pharmacokinetics: Concepts and Applications. Baltimore, MD: Lippincott Williams & Wilkins; 1995;138.

    Google Scholar 

  14. Abbott Laboratories NDA no. 13-025/S-035 submission. Available at: http://www.fda.gov/cder/ogd/rld/13025S35.pdf. Accessed: November 28, 2004.

  15. Surakitbanharn Y, Simamora P, Ward GH, Yalkowsky SH. Precipitation of pH solubilized phenytoin. Int J Pharm. 1994;109:27–33.

    Article  CAS  Google Scholar 

  16. Davio SR, McShane MM, Kaluk TJ, Zaya RM, Cole SL. Precipitation of the renin inhibitor ditekiren upon i.v. infusion: in vitro studies and their relationship to in vivo precipitation in the cynomolgus monkey. Pharm Res. 1991;8:80–83.

    Article  CAS  PubMed  Google Scholar 

  17. Greenfield JC, Loux SJ, Sood VK, Jenkins KM, Davio SR. In vitro evaluation of the plasma and blood compatibility of a parenteral formulation for ditekiren, a novel renin inhibitor pseudopeptide. Pharm Res. 1991;8:475–479.

    Article  CAS  PubMed  Google Scholar 

  18. Faulding Pharmaceuticals. Editorial: vancomycin injection. Pharm J. 1999;263:880.

    Google Scholar 

  19. Kastango ES, Hadaway L. New perspectives on vancomycin use in home care, part 2: delivery systems. Int J Pharm Comp. 2002;6:55–57.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jennifer L. H. Johnson.

Additional information

Published: January 13, 2006

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Johnson, J.L.H., Yalkowsky, S.H. Reformulation of a new vancomycin analog: An example of the importance of buffer species and strength. AAPS PharmSciTech 7, 5 (2006). https://doi.org/10.1208/pt070105

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/pt070105

Keywords

Navigation